Special Issue

Pathogenetic Aspects of Cardiovascular and Gastrointestinal Diseases

Message from the Guest Editor

The Special Issue Pathogenetic Aspects of Cardiovascular and Gastrointestinal Diseases will focus on fields of internal medicine that are currently most studied, namely nonalcoholic fatty liver disease (NAFLD), gut microbiota, and circulatory disorders. It is well established that NAFLD and arterial hypertension are common signs of metabolic syndrome, a condition associated with a greater potential of developing type 2 diabetes, lipid disorders, and cardiovascular disease. In addition, increasing evidence suggests an important role for gut microbiota in the aforementioned conditions as well as in other noncommunicable diseases. This Special Issue will constitute an interdisciplinary research space for the studies on molecular basis, pathophysiology in gastrointestinal and cardiovascular diseases. Original research and review articles covering these topics are welcome for submission to this Special Issue.

Guest Editor

Dr. Anton R. Kiselev

National Medical Research Center for Therapy and Preventive Medicine, Moscow, Russia

Deadline for manuscript submissions

closed (31 March 2024)



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/121196

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).